(Q41870911)

13 October 2017

Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound (English)

1 reference

13 October 2017

10

Colleen M Niswender

1 reference

13 October 2017

17

Craig W Lindsley

1 reference

13 October 2017

14

P Jeffrey Conn

1 reference

13 October 2017

15

Shaun R Stauffer

1 reference

13 October 2017

6

Hilde Lavreysen

1 reference

13 October 2017

7

Claire Mackie

1 reference

13 October 2017

3

Susana Conde-Ceide

1 reference

13 October 2017

13

Thomas Steckler

1 reference

13 October 2017

2

Chrysa Malosh

1 reference

José Manuel Bartolomé-Nebreda

13 October 2017

16

object named as

José Manuel Bartolomé-Nebreda

1 reference

13 October 2017

11

Carrie K Jones

1 reference

13 October 2017

Ya Zhou

1

1 reference

13 October 2017

Carlos Manuel Martínez-Viturro

4

1 reference

13 October 2017

Jesus Alcázar

5

1 reference

13 October 2017

Thomas M Bridges

8

1 reference

13 October 2017

J Scott Daniels

9

1 reference

13 October 2017

Gregor J Macdonald

12

1 reference

13 October 2017

language of work or name

English

0 references

publication date

4 July 2015

1 reference

Bioorganic & Medicinal Chemistry Letters

13 October 2017

1 reference

13 October 2017

25

1 reference

13 October 2017

17

1 reference

13 October 2017

3515-3519

1 reference

Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

A unique industrial-academic collaboration towards the next generation of schizophrenia therapeutics

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

Section I. The cholinergic system

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4535329

10.1016/J.BMCL.2015.06.096

5 June 2018

Identifiers

DOI

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

26183084

1 reference